Progesterone treatment to prevent preterm birth.
The publication in 2003 of two large randomised trials of progesterone therapy to prevent preterm delivery has generated renewed interest in this treatment and has added substantial numbers of subjects to previously published small trials. The randomised trials of progestogens have generally shown efficacy in reducing the rate of recurrent preterm delivery in women with singleton pregnancies who were at high risk for preterm labour and delivery. Most of the successful trials have employed 17alpha-hydroxyprogesterone caproate, and one trial has reported positive results using progesterone vaginal suppositories. The administration of 17alpha-hydroxyprogesterone caproate or progesterone suppositories to women with these high-risk pregnancies showed a significant protective effect for preterm birth in six of the seven published trials. No successful trials of progestogens have been reported for women at risk for preterm delivery because of multiple gestations. Trials of progestogens after the occurrence of symptoms of labour have shown them to be ineffective in prolonging pregnancy.
Department of Obstetrics and Gynecology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA. pmeis@wfubmc.edu
Paul J
PJ
Meis
Alicia
A
Aleman
D005260:Female; D006801:Humans; D011247:Pregnancy; D047928:Premature Birth / Q000517:prevention & control*; D011374:Progesterone / Q000502:physiology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D015149:Tocolytic Agents / Q000627:therapeutic use
D015149:Tocolytic Agents; D011374:Progesterone